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Abstract 1 
Recent studies have demonstrated that IGF-I associates with VN through IGF-binding proteins 2 
(IGFBP) which in turn modulate IGF-stimulated biological functions such as cell proliferation, 3 
attachment and migration. Since IGFs play important roles in transformation and progression of breast 4 
tumours, we aimed to describe the effects of IGF-I:IGFBP:VN complexes on breast cell function and 5 
to dissect mechanisms underlying these responses. In this study we demonstrate that substrate-bound 6 
IGF-I:IGFBP:VN complexes are potent stimulators of MCF-7 breast cell survival, which is mediated 7 
by a transient activation of ERK/MAPK and sustained activation of PI3-K/AKT pathways. 8 
Furthermore, use of pharmacological inhibitors of the MAPK and PI3-K pathways confirms that both 9 
pathways are involved in IGF-I:IGFBP:VN complex-mediated increased cell survival. Microarray 10 
analysis of cells stimulated to migrate in response to IGF-I:IGFBP:VN complexes identified 11 
differential expression of genes with previously reported roles in migration, invasion and survival 12 
(Ephrin-B2, Sharp-2, Tissue-factor, Stratifin, PAI-1, IRS-1). These changes were not detected when 13 
the IGF-I analogue ([L24][A31]-IGF-I), which fails to bind to the IGF-I receptor, was substituted; 14 
confirming the IGF-I-dependent differential expression of genes associated with enhanced cell 15 
migration. Taken together, these studies have established that IGF-I:IGFBP:VN complexes enhance 16 
breast cell migration and survival, processes central to facilitating metastasis. This study highlights 17 
the interdependence of ECM and growth factor interactions in biological functions critical for 18 
metastasis and identifies potential novel therapeutic targets directed at preventing breast cancer 19 
progression.20 
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Introduction 1 
The insulin-like growth factor (IGF) system is known to have roles not only in normal mammary 2 
gland development (1), but also has well documented roles in the development and progression of 3 
numerous malignancies, including breast cancer (2, 3).  The IGF ligands (IGF-I and IGF-II) have been 4 
implicated in breast cancer risk (4) and circulating levels of IGF-I have been correlated with increased 5 
risk in several other epithelial cancers (5). IGFs function to promote proliferation, stimulate 6 
transformation in breast cells (6) and also increase breast cell migration and invasion (7). In particular, 7 
the IGFs protect breast cancer cells from apoptosis and promote cell survival (8). Moreover, the type-8 
1 IGF receptor (IGF-1R) has been shown to be over-expressed in a variety of human breast cancer cell 9 
lines as well as in patient tumour biopsies (9-11). Taken together, these data suggest that the IGF 10 
system plays an important role in breast cancer progression.  11 
Components of the IGF system have been reported to interact with ECM proteins, including 12 
fibronectin, collagen IV and vitronectin (VN) and modulate cancer cell function (7, 12, 13). IGF-II 13 
has been shown to bind to VN directly (14), while IGF-I binds to VN indirectly through IGF binding 14 
proteins (IGFBP) -2, -3, -4 and -5 to form a heterotrimeric IGF-I:IGFBP:VN complex (13, 15). 15 
Furthermore, these IGF-I:IGFBP:VN complexes have been shown to be involved in stimulating 16 
migration of epithelial cells such as keratinocytes (15-17) and breast cells (7, 13, 15) via increased 17 
PI3-K/AKT signalling and co-operation between IGF-1R and VN-binding integrins (7). 18 
Given that functional effects of IGF-I:IGFBP:VN complexes on breast cell migration have 19 
been demonstrated (7) we aimed to further investigate the regulatory networks involved in the IGF-20 
I:IGFBP:VN-stimulated breast cell migration, and their involvement in other processes involved in 21 
breast cancer metastasis such as cell proliferation, apoptosis and cell cycle progression. Study of these 22 
processes could demonstrate the role of the IGF-I system and its interactions with the ECM in breast 23 
cancer progression by increasing the ability of breast cells to migrate, invade and survive in hostile 24 
microenvironments. In this study we report that substrate-bound IGF-I:IGFBP:VN complexes 25 
stimulate increased MCF-7 breast cell survival via involvement of the IGF-1R and subsequent 26 
activation of PI3-K/AKT and ERK/MAPK pathways. Microarray analysis of cells stimulated to 27 
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migrate in response to the IGF:IGFBP:VN complexes demonstrates, for the first time, that these 28 
substrate-bound complexes stimulate an IGF-1R-dependant change in the expression of genes known 29 
to be involved in cell motility, migration, as well as cell survival. 30 
 31 
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Materials and Methods 32 
Proteins and Reagents 33 
Human VN and anti-ERK 1/2 polyclonal antibody was purchased from Promega (Annandale, NSW, 34 
Australia). Human IGF-I, [L24][A31]-IGF-I analogue and IGFBP-5 was purchased from Novozymes 35 
(Adelaide, SA, Australia) with anti-AKT polyclonal antibody and IGFBP-3 (N109D) from Upstate 36 
Biotech (Lake Placid, NY, USA). IGFBP-3 (N109D) is found to be biologically more stable for in 37 
vitro studies and its use has been previously reported (7, 18-20). Monoclonal antibodies to phospho-38 
AKT (Ser473), phospho-ERK 1/2 (Thr202/Tyr204), phospho-IGF-1Rβ (Tyr1135/1136) and cleaved 39 
caspase-7 (Asp198) were purchased from Cell Signaling Technology (Beverly, MA, USA). All other 40 
reagents were from Sigma-Aldrich (Castle Hill, NSW, Australia), unless otherwise stated. 41 
 42 
Cell culture 43 
The MCF-7 human breast carcinoma cell line (American Type Culture Collection: ATCC, Manassas, 44 
VA), was grown in Dulbecco’s Modified Eagle’s Media/Ham’s F12 (DMEM/F12) media (1:1) 45 
(Invitrogen, VIC, Australia) containing 10% fetal calf serum (FCS) (HyClone, UT, USA), 1% 46 
Penicillin + Steptomycin (Invitrogen) and 0.01% Gentamycin (Invitrogen). MCF-10A cells were a 47 
kind gift from Dr Janet Martin (Kolling Institute of Medical Research, Australia) and were maintained 48 
in DMEM/F12 (1:1) containing 15 mM HEPES, 5% horse serum (HS) (Invitrogen), 10 μg/mL bovine 49 
insulin, 20 ng/mL EGF, 50 ng/mL cholera enterotoxin and 0.5 μg/mL hydrocortisone. The identity of 50 
both cell lines was authenticated using STR profiling (CellBank Australia).  51 
 52 
Treatment approach for in vitro studies investigating IGF:VN interactions 53 
To more accurately mimic the in vivo cellular environment in which cells are not constantly exposed 54 
to growth factors in solution, but rather, interact with components of the ECM, we adopted the 55 
strategy of monitoring the effects of IGF-I present as a complex with VN for this study. Growth 56 
factors and VN were pre-bound to culture-ware, as well as the lower chamber and under-surface of 57 
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Transwells® (Corning Inc., NY, USA) prior to cell seeding according to procedures previously 58 
described (7, 13, 15, 16, 21, 22) 59 
  60 
MTS assay for cell viability  61 
MCF-7 cells were serum-starved for 4 hours before seeding 1 x104 cells into 96-well plates pre-coated 62 
with VN, IGF-I and IGFBP-3 or -5 combinations. To assess cell viability after exposure to 63 
pharmacological inhibitors, serum-starved cells were incubated with inhibitors (LY294002; 20 µM 64 
and U0126; 10 µM) for 1 hour at 37 C before seeding and cellular viability assessed using the 65 
CellTitre 96® AQueous One Solution Cell Proliferation Assay (MTS) (Promega), as previously 66 
described (7).  67 
 68 
Transwell® Migration assay 69 
Migration assays were performed as described previously (7, 13, 15, 23). MCF-7 cells were serum-70 
starved for 4 hours and 2 x105 cells suspended in DMEM-SFM + 0.05% BSA seeded onto the upper-71 
surface of 12-µm pore Transwell® inserts pre-coated on the under-surface with VN, IGF-I and IGFBP 72 
combinations. Cells that had migrated after 5 hours to the under-surface of the Transwell® membrane 73 
were fixed, stained with 0.01% Crystal Violet and the stain was extracted in 10% acetic acid and 74 
quantified at 595 nm.  75 
 76 
Western immunodetection for assessment of signal transduction 77 
Subconfluent MCF-7 cells were serum-starved for 4 hours, harvested and allowed to recover for 30 78 
minutes at 37 C.  For inhibition studies, cells were pre-incubated with pharmacological inhibitors 79 
(LY294002; 20 µM and U0126; 10 µM) for 1 hour at 37 C. Cells were seeded onto 6-well plates 80 
coated with VN, IGF-I and IGFBP-3 or -5 combinations and incubated for the indicated times before 81 
total protein was collected and Western immunodetection was performed as previously described (7). 82 
SDS-PAGE-resolved protein samples (10 µg) were probed with anti-phospho ERK 1/2 (1:2000), anti-83 
phospho AKT (1:2000), anti-phospho IGF-1Rβ (1:2000) or anti-cleaved caspase-7 (1:5000) 84 
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monoclonal antibodies. Membranes were then incubated with secondary antibody (1:5000). 85 
Membranes were subsequently stripped and total protein levels validated for equal loading using anti-86 
ERK 1/2, anti-AKT, anti-IGF-1R, or anti-GAPDH monoclonal antibodies. 87 
 88 
Flow cytometric analysis of cell cycle progression and apoptosis 89 
MCF-7 cells were seeded onto 6-well plates, coated as described above, and incubated at 37 C for 90 
desired time intervals. Non-adherent and adherent cells were then collected, pelleted and resuspended 91 
in cold PBS before fixing with ethanol.  Cells were then stained with propidium iodide (1 mg/mL) 92 
containing RNase (2 mg/mL) for 15 minutes at 37 C prior to flow cytometric analysis (FC500, 93 
Beckman Coulter; NSW, Australia). 94 
 95 
Microarray analysis of differential gene expression 96 
Total RNA was isolated using TRI Reagent (Ambion, Austin, TX, USA) following the 97 
manufacturer’s protocols from MCF-10A cells which had migrated onto the under-surface of 98 
Transwell® membranes in response to VN, IGFBP-5+VN, IGF-I+VN and IGF-I+IGFBP-5+VN 99 
treatments (Treatment samples), or from non-migrated MCF-10A cells (suspended in SFM) which 100 
remained on the upper-surface of the membrane (Control sample). RNA was isolated from three 101 
independent replicate experiments where RNA was pooled from 12 Transwell® inserts for each 102 
treatment. Subsequent target synthesis using biotin-labelled aRNA was performed using the 103 
MessageAmp™ II-Biotin Enhanced Single Round aRNA Amplification Kit (Ambion), according to 104 
the manufacturer’s protocols. Fragmented aRNA probe samples (15 µg) were hybridized to Test3 and 105 
GeneChip® Human Genome U133 Plus 2.0 arrays for 16 hours at 45 C in a rotary incubator and 106 
processed in an Affymetrix Fluidics Station 400. Probe arrays were scanned with an Affymetrix 107 
GeneChip® Scanner 3000 at a wavelength of 570 nm. 108 
For data analysis, probe intensity data was imported to GeneSpring GX 7.3 and pre-processed 109 
using Robust Multi-chip Average, with GC-content background correction (GC-RMA). Differentially 110 
expressed genes were identified from pairwise comparison, a fold change threshold of 1.8 and one-111 
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way ANOVA (parametric test, assuming unequal variances) with ‘Benjamin and Hochberg false 112 
discovery rate’ (BHFDR) for multiple testing correction (p = 0.05). Functional analysis of target 113 
genes, gene ontology, canonical pathway and functional network analyses were performed using 114 
Ingenuity Pathway Analysis (IPA) tools (Ingenuity® Systems, www.ingenuity.com). KEGG pathway 115 
analysis was applied to the same data set using the DAVID online functional annotation tool 116 
(http://david.niaid.nih.gov/david/ease.htm). 117 
 118 
Quantitative real-time PCR (qRT-PCR) analysis of differential gene expression 119 
RNA was extracted from MCF-7 breast cell lysates using the RNeasy® Plus Mini Kit (Qiagen VIC, 120 
Australia) following the manufacturer’s instructions, whereas for MCF-10A cells RNA isolated for 121 
the microarray analysis was used for qRT-PCR analysis. First strand cDNA synthesis was performed 122 
using the SuperScript® III First-Strand Synthesis SuperMix kit (Invitrogen) following the 123 
manufacturer’s instructions.  All primers were designed using Primer Express 2.0 software (Applied 124 
Biosystems) (Refer Table 1 for oligonucleotide primer sequences). All reactions were performed in 125 
triplicates using SYBR green (Applied Biosystems) and ABI Prism 7300 Sequence Detection System 126 
(Applied Biosystems). PCR amplification commenced with an initial 10 minute denaturation step at 127 
95 C followed by 40 cycles of 95 C for 15 seconds and 60 C for 1 minute. All real-time PCR reactions 128 
included a post-amplification dissociation curve analysis. Target gene expression for each sample was 129 
normalised to 18S rRNA values of the corresponding samples.  130 
 131 
Statistical Analysis 132 
In all cases, data analysis was performed using one-way ANOVA with Tukey’s post-hoc tests, unless 133 
otherwise stated. Differences of p<0.05 (95% confidence interval) were considered to be statistically 134 
significant.135 
 9 
 
 136 
Results 137 
Substrate-bound IGF-I:IGFBP:VN complexes are potent stimulators of breast cancer cell survival 138 
To determine if IGF:IGFBP:VN complexes enhance breast cancer cell survival we 139 
investigated the effects of these complexes on MCF-7 cell viability, cell cycle and apoptosis. IGF-140 
I+IGFBP-3+VN and IGF-I+IGFBP-5+VN complexes were observed to stimulate significant increases 141 
(p<0.05) in cell viability compared to the VN control wells at 48 and 72 hour post-seeding of MCF-7 142 
cells (Fig. 1 A). No significant differences in cell viability were observed at 24 hours. IGF-I+IGFBP-143 
3+VN and IGF-I+IGFBP-5+VN induced similar effects on MCF-7 cell viability over 72 hours, with 144 
no significant differences observed between the two IGF-I:IGFBP:VN complexes (Fig. 1 A). The 145 
increases in cell viability induced by substrate-bound IGF-I:IGFBP:VN complexes were similar to 146 
that observed for cells incubated in 10% FCS (Fig. 1 A). Moreover, substrate-bound IGF-147 
I:IGFBP:VN-stimulated proliferation was dependent on heterotrimeric complex formation as no 148 
significant changes in cell viability were observed in cells incubated with the individual components 149 
of the complex in presence of VN (VN alone, IGF-I+VN, IGFBP-3+VN or IGFBP-5+VN) 150 
(Supplemental Fig. 1 A). IGF-I or IGFBP alone treatments were not tested as cells did not adhere to 151 
the culture-ware in the absence of VN or serum (data not shown). Effects similar to the pre-bound 152 
setup were observed when cells were exposed to the complex present in solution-phase (Supplemental 153 
Fig. 1 B).  154 
To ascertain the effect of IGF-I:IGFBP:VN complexes on MCF-7 cell survival, we 155 
determined its ability to inhibit apoptosis induced by serum deprivation by assaying the cleavage of 156 
caspase-7 and cell cycle progression. Incubation of MCF-7 cells with substrate-bound IGF-I+IGFBP-157 
5+VN complexes resulted in a substantial decrease in the levels of cleaved caspase-7 over 72 hours 158 
compared to cells incubated in SFM or VN alone control treatments (Fig. 1 B), indicating a decrease 159 
in the induction of apoptosis by IGF-I:IGFBP:VN complexes. The cell cycle progression of MCF-7 160 
cells was analysed using flow cytometry to confirm the effects of IGF-I:IGFBP-5:VN complexes on 161 
apoptosis. After 48 and 72 hours exposure, a significant reduction (p<0.05) in the number of apoptotic 162 
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MCF-7 cells incubated with IGF-I:IGFBP-5:VN complexes, compared to the SFM-treated (control) 163 
cells was evident. Exposure to IGF-I:IGFBP-5:VN complexes increased the number of cells in G1 164 
phase compared to SFM control treated cells over 72 hours (Fig. 1 C).  165 
 To further investigate IGF-I:IGFBP:VN complex-mediated pro-survival effects, MCF-7 cells 166 
were treated with cytotoxic drugs, Adriamycin (0.1 µg/mL) and Mitomycin C (1 µg/mL), at 167 
concentrations that significantly inhibited cell viability by 50 ± 9% after 48 hours of incubation in 168 
standard growth media (10% FCS) (Fig. 1 D). Previous reports have demonstrated that these cytotoxic 169 
drugs induce apoptosis in MCF-7 cells within 48 hours (24, 25). Our study demonstrates that MCF-7 170 
cells exposed to substrate-bound IGF-I:IGFBP-3/-5:VN complexes were protected from drug-induced 171 
apoptosis with significantly greater (p<0.05) viability than cells exposed to VN alone (Fig. 1 D). The 172 
protective effect observed in response to IGF-I:IGFBP:VN complexes was also significantly increased 173 
above that of 10% FCS containing media (Fig. 1 D), demonstrating the potent anti-apoptotic or pro-174 
survival effect of substrate-bound IGF-I:IGFBP:VN complexes. Taken together, the above evidences 175 
indicate that substrate-bound IGF-I:IGFBP:VN complexes are potent stimulators of breast cancer cell 176 
survival eliciting protection of cells from serum starvation- or drug-induced apoptosis. 177 
 178 
IGF-I:IGFBP:VN complex-stimulated breast cancer cell survival is mediated via the ERK/MAPK and 179 
PI3-K/AKT pathways 180 
To investigate possible mechanisms underlying the increased cell survival in response to IGF-181 
I:IGFBP:VN complexes, we examined the activation of the PI3-K/AKT and ERK/MAPK intracellular 182 
signalling pathways as they are known to play a role in IGF-I:IGFBP:VN-induced breast cell 183 
migration (7). MCF-7 cells were incubated in wells pre-coated with VN (1 μg/mL), either alone or in 184 
the presence of IGF-I (30 ng/mL) and IGFBP-3 or -5 (90 ng/mL) at doses determined to be optimal 185 
for simultaneous monitoring of the activation of IGF1R, ERK1/2 and AKT (Supplemental Fig. 2).  186 
The IGF-I:IGFBP:VN complexes induced rapid and transient activation of ERK 1/2 within 10 187 
minutes and 1 hour (Fig. 2 A and B). In contrast, IGF-1R and AKT activation induced by the IGF-188 
I:IGFBP:VN complexes was sustained for up to 3 hours and 12 hours, respectively. IGF-I:IGFBP-189 
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3:VN and IGF-I:IGFBP-5:VN complexes induced similar activation of MAPK and PI3-K/AKT 190 
pathways (Fig. 2 A and B). Moreover, the increased and sustained activation of AKT and the IGF-1R 191 
was seen only in presence of the heterotrimeric IGF-I:IGFBP:VN complexes, whereas ERK 1/2 192 
activation was seen in presence of the individual components of the complex (i.e VN alone, IGF-193 
I+VN or IGFBP-3/-5+VN) in addition to the heterotrimeric IGF-I:IGFBP:VN complex (Supplemental 194 
Fig. 3).  195 
To determine the relative contributions of PI3-K/AKT and ERK/MAPK signalling pathway 196 
activation to the increased cell survival observed in the presence of substrate-bound IGF-I:IGFBP:VN 197 
complexes, MCF-7 cells were pre-incubated with specific pharmacological inhibitors of the PI3-198 
K/AKT and ERK/MAPK pathways, LY294002 and U0126, respectively. Doses of 20 μM LY294002 199 
and 10 μM U0126 were used and observed to have minimal non-specific pathway inhibition (Fig. 2 200 
C); doses we have previously found to be specific for AKT and ERK 1/2 inhibition (7). Inhibition of 201 
both ERK 1/2 and AKT significantly decreased (p<0.05) IGF-I:IGFBP-3/-5:VN complex-stimulated 202 
MCF-7 cell viability after 72 hours (Fig. 2 D). Interestingly, similar levels of cell viability in response 203 
to substrate-bound IGF-I:IGFBP:VN complexes were observed via inhibition of ERK/MAPK or PI3-204 
K/AKT pathways. This suggests that both pathways may be involved in mediating the pro-survival 205 
effects of substrate-bound IGF-I:IGFBP:VN complexes.  206 
 207 
IGF-I:IGFBP:VN-stimulated breast cell migration is accompanied by unique changes in gene 208 
expression 209 
Migration of tumour cells from the primary site and their subsequent survival in secondary 210 
tissues are key events in the metastatic spread of breast cancer. We have previously reported 211 
substrate-bound IGF-I:IGFBP:VN complexes to be potent stimulators of cell migration in both non-212 
tumourigenic (MCF-10A) and tumourigenic (MCF-7) breast cell lines (7). In order to dissect the 213 
transcriptional changes that may mediate this enhanced migratory phenotype we performed 214 
microarray gene expression analysis of MCF-10A cells that had migrated in response to the IGF-215 
I:IGFBP:VN complex to the under-surface of Transwell® membranes. The use of the MCF-10A cell 216 
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line was deliberate to maximise the identification of any transcriptional changes that may occur when 217 
relatively non-motile cells are stimulated to migrate in response to substrate-bound complexes. RNA 218 
was isolated from MCF-10A cells which had migrated to the under-surface of 12-µm pore Transwell® 219 
insert membranes in response to VN alone, IGF-I+VN, IGFBP-5+VN and IGF-I+IGFBP-5+VN 220 
treatments (Treatment groups). RNA was also isolated from non-migrated cells (i.e. those on the 221 
upper-surface of the insert membrane) suspended in SFM (Control group). To confirm that the IGF-222 
I:IGFBP-5:VN complexes induced MCF-10A cell migration in experiments from which the RNA was 223 
isolated for microarray analysis, three random wells were fixed and stained to quantify relative levels 224 
of cell migration (Supplemental Fig. 4). Stimulation of cell migration was confirmed by a greater than 225 
2-fold increase in migration observed in IGF-I:IGFBP:VN complex-treated cells compared to that 226 
induced by VN alone (211 ± 12% of VN alone) (Supplemental Fig. 4).  227 
To identify genes that may be involved in the induction of cell migration in response to each 228 
treatment, initial pair-wise comparisons between each of the “treatment” groups  and “control” group 229 
were undertaken (Table 2 A). Statistically significant probe sets were then identified using a fold 230 
change threshold of 1.8. Given that the selection of differentially expressed genes within a microarray 231 
data-set is performed through a fold change cut-off, typically between 1.8 and 3.0 (26) we chose the 232 
lower limit of 1.8-fold as our threshold value to ensure critical genes which may not have a large 233 
magnitude of change were identified, while keeping the data set to a manageable size. As seen in 234 
Table 2 A, only a small number of transcripts were identified to be differentially expressed by VN 235 
alone (14), IGFBP-5+VN (17) and IGF-I+VN (20) treatments. Far greater numbers of transcripts 236 
(231) were identified to be differentially regulated by the IGF-I+IGFBP-5+VN treatments when 237 
compared to the control (SFM) treatment. As expected, in view of the similar levels of migration 238 
induced by VN, IGFBP-5+VN and IGF-I+VN (Supplemental Fig. 4), considerable overlap in genes 239 
differentially expressed by VN, IGFBP-5+VN and IGF-I+VN treatments was evident (Supplemental 240 
Fig. 5). Indeed, the majority of transcripts were present in all three treatments (Supplemental Fig. 5). 241 
Similarly, Principal Component Analysis (PCA) showed a clear separation of the samples into three 242 
distinct groupings (Group-1: control SFM only; Group-2: VN alone, IGF-I+VN and IGFBP-5+VN; 243 
and Group-3: IGF-I+IGFBP-5+VN) (Supplemental Fig. 6). Due to the commonality between VN, 244 
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IGF-I+VN and IGFBP-5+VN treatments and desire to reduce the complexity of analysis, differential 245 
gene expression induced by the IGF-I+IGFBP-5+VN complexes was subsequently compared to VN 246 
alone.  247 
In order to identify transcripts expressed in a unique manner by IGF-I+IGFBP-5 associating 248 
with VN, genes induced by IGF+IGFBP-5+VN treatments were directly compared to that of the VN 249 
alone treatment. This revealed 194 probe sets to be uniquely expressed by at least ± 1.8-fold in cells 250 
migrating in response to the IGF-I:IGFBP-5:VN complex. These represented 165 unique genes once 251 
the presence of repetitive probe sets were taken into consideration (Supplemental Table 1). Included 252 
among these genes were the IGF pathway-related genes SFN (+2.3), IRS-1 (-5.4) and CTGF (-2.8) 253 
(27-29).  Other genes included proteases TF (+2.7), MMP13 (-3.5), ADAMTS5 (-4.8), protease 254 
inhibitors PAI-1/SERPINE1 (+2.0), TFPI (-5.0), cell adhesion proteins FLRT2 (+2.6), CLDN1 (-5.3), 255 
cytoskeleton proteins ACTN1 (+1.8), TUBA1 (+1.9), and genes involved in transcriptional regulation, 256 
such as BHLHB2 (+2.7), MAFB (+2.4), BACH2 (-3.9) and BCL6 (-4.0). Thus a substantial number of 257 
genes were found to be uniquely regulated in migrating breast epithelial cells in response to IGF-258 
I:IGFBP-5:VN complexes.  259 
In order to place these genes in a biological context we utilized the IPA knowledge base. 260 
Processes involved with cell growth/survival were the most significant functional category, containing 261 
48 focus genes (Supplementary Table 2). Importantly, cell movement was one of the highest ranking 262 
functional categories containing 24 focus genes, including cellular migration, movement and 263 
chemotaxis of a variety of cell types (Supplementary Table 2). EFNB2, F3, PAI-I, IRS-1, BHLHB2 264 
and SFN were genes associated with a number of biological processes related to cellular movement 265 
(Supplementary Table 3). Network analysis of the differentially expressed genes was performed to 266 
further investigate the functional relationships between these genes. Cellular growth and proliferation, 267 
cell death and cellular movement were found to be the most significant biological functions associated 268 
with the highest ranking gene networks. It was observed that PI3-K, AKT and MAPK mapped to the 269 
core of the highest ranking networks and were amongst the most prominent interaction partners 270 
(Supplemental Fig. 7 A and B). These data indicate an important role for these intracellular signalling 271 
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intermediates in regulation of genes within the highest ranking networks generated from IGF-272 
I:IGFBP:VN target genes. 273 
 274 
Confirmation of unique gene expression in migrated MCF-10A cells by qRT-PCR analysis 275 
Eleven genes deemed biologically interesting because of their differential expression induced 276 
by IGF-I:IGFBP:VN complexes and their relevance to cellular movement and cell survival (Table 2 A 277 
and B) were validated by qRT-PCR analysis. The differential expression pattern of 6 up-regulated 278 
genes, EFNB2, BHLHB2, F3, SFN, PAI-1 and FLRT2, as well as 5 down-regulated genes, IRS1, 279 
CXCL14, CLDN1, TFPI and PAWR was confirmed (Fig. 3 A and B). As identified in the microarray 280 
analysis, the expression of all genes analysed by qRT-PCR in migrated MCF-10A cells remained 281 
relatively unchanged in cells exposed to VN alone, IGF-I+VN and IGFBP-5+VN treatments. 282 
Importantly, all 11 genes were confirmed to be differentially expressed by at least ± 1.8-fold in a 283 
unique manner in cells that migrated in response to the IGF-I:IGFBP-5:VN complex (Fig. 3 A and B). 284 
Furthermore, the magnitude of change for each of the 11 genes analysed showed a close concordance 285 
between the microarray and qRT-PCR analysis (Fig. 3 C) supporting the validation of the microarray 286 
data set. 287 
 288 
Differential expression of target genes is also observed in MCF-7 breast cancer cells induced to 289 
migrate in response to the IGF-I:IGFBP-5:VN complex 290 
To assess whether the differentially expressed genes identified in non-tumourigenic MCF-291 
10A cells had similar expression patterns in tumourigenic breast cells, MCF-7 cells were seeded onto 292 
Transwells® pre-coated on the under-surface with VN alone or in presence of IGF-I and/or IGFBP-5. 293 
Migrated cells were lysed after 5 hours and RNA harvested for qRT-PCR analysis. The induction of 294 
migration by substrate-bound IGF-I:IGFBP-5:VN complexes was confirmed via staining as outlined 295 
for MCF-10A cells (Supplemental Fig. 8 A). Simulation of cell migration by IGF-I:IGFBP-5:VN 296 
complexes was confirmed with a greater than 2-fold increase in migration compared to that induced 297 
by VN alone (230 ± 26% of the VN control wells) (Supplemental Fig. 8 A), consistent with data 298 
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reported previously from our laboratory (7). The qRT-PCR validation in migrated MCF-7 cells 299 
focussed on genes identified in the microarray analysis to have roles in cellular movement, migration 300 
and survival, namely, EFNB2, BHLHB2, F3, SFN, PAI-1 and IRS-1. As observed in MCF-10A cells, 301 
the expression of the selected target genes in migrated MCF-7 cells remained relatively unchanged in 302 
cells exposed to VN alone, IGF-I+VN and IGFBP-5+VN treatments (Fig. 4). Nevertheless, a greater 303 
than ± 1.8-fold change was observed in expression of all selected target genes in MCF-7 cells that 304 
migrated in response to the IGF-I:IGFBP-5:VN complex (Fig. 4). This suggests that the IGF-305 
I:IGFBP-5:VN complex stimulates changes in the expression of genes associated with cell motility 306 
and potentially drive migration not only in non-tumourigenic epithelial breast cells (MCF-10A) but  307 
also in tumourigenic breast cancer cells (MCF-7). 308 
To determine if the observed changes in MCF-7 gene expression were mediated through the 309 
IGF-1R, an IGF-I analogue, [L24][A31]-IGF-I, which does not bind to the IGF-1R but retains its ability 310 
to bind IGFBPs, was substituted for native IGF-I in the migration assays. This analogue supports the 311 
formation of the trimeric IGF-I:IGFBP:VN complex; however, the complex cannot activate the IGF-312 
1R (30, 31). Assays evaluating the migration of MCF-7 cells seeded onto Transwells® pre-coated with 313 
VN alone, IGF-I+IGFBP-5+VN or [L24][A31]-IGF-I+IGFBP-5+VN revealed no significant changes in 314 
cell migration in presence of the [L24][A31]-IGF-I:IGFBP-5:VN complex compared to VN alone 315 
(Supplemental Fig. 8 B). Changes in select target gene expression in MCF-7 cells stimulated to 316 
migrate in response [L24][A31]-IGF-I+IGFBP-5+VN complexes were confirmed by qRT-PCR. In 317 
contrast to the IGF-I:IGFBP-5:VN-induced differential gene expression, no significant changes 318 
(p<0.05) in select target gene expression were observed in MCF-7 cells that had migrated in response 319 
to the [L24][A31]-IGF-I+IGFBP-5+VN complex compared to VN alone (Fig. 4). These data suggest 320 
that IGF-1R activation is crucial to the differential gene expression induced in breast cancer cells 321 
stimulated to migrate in response to IGF-I:IGFBP:VN complexes. 322 
323 
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 324 
Discussion 325 
The ability of cells to invade and migrate from the primary tumour site and subsequently survive 326 
within distal microenvironments is critical for breast cancer metastasis in vivo (32). Altered 327 
interactions between mitogenic hormones and growth factors, such as IGFs, and the ECM are 328 
considered to be one of the more important factors contributing towards breast cancer progression. In 329 
view of this, previous work within our laboratory has demonstrated that IGF-I can associate with the 330 
ECM protein, VN, through IGFBP-2, -3, -4 and -5, forming heterotrimeric complexes of IGF-331 
I:IGFBP:VN that are capable of stimulating cell migration (7, 13, 15)  332 
To study the involvement of IGF-I and VN interactions in breast cell functions, we adopted 333 
the strategy of pre-binding IGFs +/- IGFBP-3/-5 to VN-coated wells to form a substrate-bound 334 
complex. In vivo, the binding of growth factors to ECM proteins can result in maintenance of a 335 
uniform growth factor concentration, alter diffusion rates through the matrix regulating its local 336 
concentration, and also modulate growth factor receptor interactions (33). Thus, perhaps a better 337 
strategy for mimicking the in vivo situation in in vitro investigations of growth factors on target cells 338 
would be to pre-bind the growth factors to a biologically relevant substrate prior to monitoring their 339 
effects on cellular function. Indeed, it has been reported that IGFBP-5 pre-bound to ECM enhanced 340 
the actions of IGF-I on smooth muscle cell DNA synthesis, whereas IGFBP-5 added in solution, 341 
without any ECM substrate, failed to render similar effects (34). As reported herein, we also adopted 342 
substrate-bound approaches to more accurately mimic events in vivo hence making our results 343 
relevant to the microenvironment to which cells would be exposed to in vivo.  344 
IGFs stimulate mammary epithelial cell proliferation both in vivo and in vitro (35), and have 345 
demonstrated roles in the sustenance, growth and survival of a number of cancers, including breast 346 
cancer (36, 37). IGFs have well documented anti-apoptotic activity (38, 39) and there is increasing 347 
evidence that increased levels of VN enhance cell survival in tumours (40, 41). The studies reported 348 
herein demonstrate that the anti-apoptotic effects of the IGF-I:IGFBP:VN complexes correlate well 349 
with the enhanced cell viability observed over 72 hours (Fig. 1). This provides evidence that IGF-I 350 
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bound to VN within the ECM surrounding breast tumours may enhance breast cancer cell survival, 351 
contributing to a key process relevant to breast cancer progression.   352 
It is well established that dysregulation and/or over-expression of elements of the IGF system 353 
can lead to aberrant IGF-1R signalling which can lead to the development of an invasive phenotype 354 
(37). As there is a concomitant increase in expression of VN and VN-binding integrins at the leading 355 
edge of migratory tumour cells (40, 42, 43), it is important to elucidate the mechanisms behind 356 
IGF:IGFBP:VN complex-stimulated effects on breast cell function. It has been shown that IGF-357 
I:IGFBP:VN stimulates an increase in breast cell migration through the activation of PI3-K/AKT 358 
pathway and the association of IGF-1R and VN-binding integrins (7). However, to date the 359 
mechanisms underlying enhanced cell survival in response to IGFs associated with VN have remained 360 
unclear. We demonstrate herein that the IGF-I:IGFBP:VN complexes stimulate an increase in breast 361 
cancer cell survival through the sustained activation of the IGF-1R, leading to the transient activation 362 
of ERK/MAPK and sustained activation of the PI3-K/AKT pathways (Fig. 2 A and B). These data 363 
complement our previously reported data (7). Signalling experiments were also performed over a 364 
longer duration (up to 24 hours) in order to investigate long term effects on key signalling pathways 365 
that may potentiate breast cell survival. The application of pharmacological inhibitors against these 366 
pathways also demonstrate that both ERK/MAPK and PI3-K/AKT pathways are involved in the IGF-367 
I:IGFBP:VN-stimulated increase in breast cancer cell survival (Fig. 2 D). Even though AKT and IGF-368 
1R activation was seen only in the presence of the IGF-I:IGFBP:VN complexes, ERK 1/2 activation 369 
for the initial 10 minutes was observed even in the presence of the individual components of the 370 
complex (VN only, IGF-I+VN and IGFBP-3/-5+VN). This may be due to the ligation of VN-binding 371 
integrins expressed by MCF-7 cells (αvβ1, αvβ5) by “VN alone” which could be sufficient to induce 372 
transient ERK 1/2 activation similar to that induced by the IGF-I:IGFBP:VN complexes. The AKT 373 
and MAPK pathways have been reported to be hyperactivated in many human malignancies (44, 45) 374 
and clinical studies have correlated increased AKT and/or MAPK expression and activation with 375 
more invasive and metastatic disease (46, 47). As such, our results demonstrating substrate-bound 376 
IGF-I:IGFBP:VN complexes to be potent activators of these signalling pathways lends support to a 377 
role for these growth factor:ECM complexes in promoting breast cancer progression.  378 
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While the intracellular signalling pathways relaying IGF signals to the nucleus are relatively 379 
well understood, the target genes which mediate IGF’s biological actions are largely unknown. The 380 
emergence of gene expression profiling using DNA microarray approaches has added valuable new 381 
information to our understanding of the molecular events underpinning IGF actions. To date these 382 
have focused on identifying mitogenic and anti-apoptotic IGF target genes in specific cell types (48-383 
50). However, few global gene expression studies aimed at identifying genes involved in IGF-384 
stimulated cell migration and metastasis have been undertaken. While genes studied in isolation have 385 
been reported to modulate IGF-stimulated cell migration, a global picture of differential gene 386 
expression is wanting. Additionally, the impact of the ECM on IGF-induced gene expression has also 387 
not been taken into consideration. As such, our study is the first to use microarray expression profiling 388 
to identify potential mediators of the enhanced breast cell migration stimulated by substrate-bound 389 
IGF-I:IGFBP:VN complexes.  390 
Breast cell migration was significantly enhanced in presence of the IGF-I:IGFBP-5:VN 391 
complex compared to VN only control treatments (Supplemental Fig. 4 and 8) with previous studies 392 
demonstrating that a significant proportion of cells (greater than 15%) seeded onto the upper-chamber 393 
of the Transwell® migrate to the under-surface in presence of the pre-bound growth factor:ECM 394 
protein complexes (51). Microarray analyses of breast epithelial MCF-10A cells that had migrated to 395 
the under-surface of the Transwell® in presence of the IGF-I:IGFBP-5:VN complex identified a 396 
number of unique differentially-expressed genes involved in cell movement, growth and survival, 397 
including F3, SFN, EFNB2, PAI-I, IRS-1 and BHLHB2 (Table 2 B and C). Intriguingly, similar 398 
expression of selected target genes were also observed in weakly metastatic MCF-7 breast cancer 399 
cells that had migrated in response to IGF-I:IGFBP:VN complexes (Fig. 4), highlighting the potential 400 
role of these genes in IGF-I:IGFBP:VN complex-stimulated migration. Several studies provide 401 
evidence for the involvement of these genes in stimulating cell movement. For example, Tissue factor 402 
(F3) is often found in the leading edge of tumours where it can modulate tumour cell adhesion and 403 
migration (52), whereas ephrin-B2 (EFNB2) can promote cell migration by mechanisms involving 404 
modulation of integrin activity, actin cytoskeleton reorganization and lamellipodia formation (53). 405 
Plasminogen activator inhibitor-1 (PAI-1) functions to increase filipodia formation (54) and migration 406 
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through the uPAR-dependent attachment of cells to VN (55, 56). In addition to its role in stimulating 407 
cell migration and motility, F3 and EFNB2 also contribute towards metastatic tumour dissemination 408 
via increasing tumour cell survival (57, 58). Sharp-2 (BHLHB2) and Stratifin (SFN) have well 409 
documented roles in proliferation (59), apoptosis (60) and cell cycle regulation (61). The differential 410 
gene expression identified herein will not only increase our understanding of the mechanisms 411 
responsible for IGF-I:IGFBP:VN-stimulated migration, but may also provide insights into the early 412 
molecular events promoting breast cell metastasis, whereby tumour cells migrating out of the primary 413 
tumour site may gain the ability to survive within their new microenvironment.  414 
Network analysis on genes identified to be differentially regulated by IGF-I:IGFBP:VN 415 
complexes revealed PI3-K/AKT and MAPK to be central nodes in the highest ranking molecular 416 
networks. Previous reports have demonstrated that activation of PI3K/AKT and/or MAPK pathways 417 
by growth factors, such as IGF-I and EGF, can modulate the expression of genes identified in our 418 
microarray analysis, including SFN (62), BHLHB2 (63), Ephrins (64) and IRS-1 (65). Indeed, the use 419 
of IGF-I analogue [L24][A31]-IGF-I demonstrated a critical role for IGF-1R activation and thus 420 
downstream PI3-K/AKT and MAPK signalling cascades in regulation of the unique gene expression 421 
in migrating breast cells. Future studies using pharmacological inhibitors of these signalling 422 
pathways, along with loss-and-gain of function studies will be pivotal in determining if the genes 423 
identified herein have functional roles in mediating IGF-I:IGFBP:VN-stimulated breast cancer cell 424 
migration and survival.  425 
In summary, for the first time we have identified IGF-I:IGFBP:VN-induced changes in gene 426 
expression that may be central to the enhanced cell migration and survival observed in breast cancer 427 
cells exposed to these growth factor:ECM complexes. An increased understanding of the 428 
interdependence of ECM and growth factor interactions and specifically IGF-I with VN, will be of 429 
particular importance for the dissemination of breast cancer in vivo. Importantly, this study identifies 430 
potential novel therapeutic targets which can be pursued for the development of therapies to prevent 431 
breast cancer progression. 432 
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 626 
Tables 627 
 628 
Table 1: Details of primers used for qRT- PCR 629 
Affymetrix 
probe 
identifier 
Gene 
Symbol 
Primer sequence GenBank 
Accession 
number 
Amplicon 
position 
202668_at EFNB2 F: AGAGTTCCCTGCAACCAATTG R: GACGATCATACAAGCAAGGCAT BF001670 3587-3730 
201170_s_at BHLHB2 F: CAACGGCATATGGAGTGTCCT R: CACGATCAGCAATCAGGCAT NM_003670 2444-2593 
204363_at F3 F: TTACCTGGAGACAAACCTCGGA R: AAAACATCCCGGAGGCTTAGG NM_001993 525-659 
209260_at SFN F: ACTCTTCTTGC AGCTGTTGAGC R: TCAATTCCTACGATCAGAGGCA BC000329 990-1140 
1568765_at PAI-1 F: CCCCATCACCCAGTAACAAGAA R: CTCTTAATGCTTTCCCAGCGAT BC020765 336-455 
204359_at FLRT2 F: CCATATGCTGATTTGCTTCTGG R: AAGTGTGCGACATGGTAGGTCT NM_013231 6996-7100 
204686_at IRS-1 F: TCATTGACTGAACTGCACGTTC R: AAACCCATTCTCTCATGACACG NM_005544 4930-5091 
218002_s_at CXCL14 F: ATGAAGCCAAAGTACCCGCAC R: TTCCAGGCGTTGTACCACTTG NM_004887 631-773 
218182_s_at CLDN1 F: TGAAGTGCTTGGAAGACGATGA R: TGACCAAATTCGTACCTGGCA NM_021101 534-708 
213258_at TFPI F: ACTGAAACCTCCCACCTAGCTG R: GGAAGATTGCTTGAGCCCA BF511231 2738-2869 
204005_s_at PAWR F: CCACCTAGAACAGTTTCAGGCA R: GTACCTGAAACATTTGCATCCC NM_002583 938-1068 
NA 18S F: GATCCATTGGAGGGCAAGTCT R: CAAGATCCAACTACGAGCTTTTT NR_003286 589-691 
 630 
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 632 
Table 2 A: Number of probe sets identified as differentially regulated in Pairwise Comparisons. 633 
The table demonstrates the number of statistically significant probe sets which were identified to be at 634 
least ± 1.8-fold differentially expressed in each pairwise comparison (p<0.05). 635 
 636 
Pairwise comparison VN IGF-I+VN IGFBP-5+VN IGF-I+IGFBP-5+VN 
Control 14 20 17 231 
VN - 0 0 194 
 637 
 638 
Table 2 B: The thirty most significantly up-regulated probe-sets in cells migrating in response to IGF-639 
I:IGFBP-5:VN complexes. 640 
 641 
Affy ID Genbank Gene Symbol Description Fold Change
209446_s_at BC001743 C7ORF44 chromosome 7 open reading frame 44 2.766
204363_at NM_001993 F3 coagulation factor III (thromboplastin, tissue factor) 2.699
201170_s_at NM_003670 BHLHB2 basic helix-loop-helix domain containing, class B, 2 2.671
204359_at NM_013231 FLRT2 fibronectin leucine rich transmembrane protein 2 2.602
202668_at BF001670 EFNB2 ephrin-B2 2.435
205074_at NM_003060 SLC22A5 solute carrier family 22, member 5 2.432
225424_at AB046780 GPAM glycerol-3-phosphate acyltransferase, mitochondrial 2.417
218559_s_at NM_005461 MAFB v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) 2.357
209260_at BC000329 SFN stratifin 2.335
200799_at NM_005345 HSPA1A heat shock 70kDa protein 1A 2.29
223062_s_at BC004863 PSAT1 phosphoserine aminotransferase 1 2.256
232060_at AK000776 cDNA clone CS0DD009YB17 of Neuroblastoma Cot 50-normalized of Homo sapiens 2.187
206753_at AF086735 RDH16 retinol dehydrogenase 16 (all-trans and 13-cis) 2.16
227556_at AI094580 NME7 non-metastatic cells 7, protein expressed in (nucleoside-diphosphate kinase) 2.138
229125_at AA456955 ANKRD38 ankyrin repeat domain 38 2.108
209834_at AB017915 CHST3 carbohydrate (chondroitin 6) sulfotransferase 3 2.078
242138_at BF060783 DLX1 distal-less homeo box 1 2.045
1568765_at BC020765 PAI-1 or SERPINE1
serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), member 1 2.031
213562_s_at BF979497 SQLE squalene epoxidase 2.025
229105_at AV717094 LYPDC1 LY6/PLAUR domain containing 1 2.014
213577_at AA639705 SQLE squalene epoxidase 2.01
201242_s_at BC000006 ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 1.962
227616_at BG481877 BCL9L B-cell CLL/lymphoma 9-like 1.961
214141_x_at BF033354 SFRS7 splicing factor, arginine/serine-rich 7, 35kDa 1.957
209218_at AF098865 SQLE squalene epoxidase 1.943
212242_at AL565074 TUBA1 tubulin, alpha 1 (testis specific) 1.937
227164_at AL521786 SFRS1 Splicing factor, arginine/serine-rich 1 (splicing factor 2, alternate splicing factor) 1.931
211965_at BE620915 ZFP36L1 zinc finger protein 36, C3H type-like 1 1.884
211538_s_at U56725 HSPA2 heat shock 70kDa protein 2 1.882
232375_at AI539443 STAT1 Signal transducer and activator of transcription 1 1.866  642 
 643 
 644 
 645 
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Table 2 C: The thirty most significantly down-regulated probe-sets in cells migrating in response to 646 
IGF-I:IGFBP-5:VN complexes. 647 
 648 
Affy ID Genbank Gene Symbol Description Fold Change
218723_s_at NM_014059 RGC32 response gene to complement 32 -17.76
205960_at NM_002612 PDK4 pyruvate dehydrogenase kinase, isoenzyme 4 -14.45
219799_s_at NM_005771 DHRS9 dehydrogenase/reductase (SDR family) member 9 -9.35
217028_at AJ224869 CXCR4 chemokine (C-X-C motif) receptor 4 -8.13
1562321_at AL832708 PDK4 pyruvate dehydrogenase kinase, isoenzyme 4 -7.75
235419_at AW612461 MIG-6 ERBB receptor feedback inhibitor 1 -7.09
218002_s_at NM_004887 CXCL14 chemokine (C-X-C motif) ligand 14 -6.17
204686_at NM_005544 IRS1 insulin receptor substrate 1 -5.38
218182_s_at NM_021101 CLDN1 claudin 1 -5.26
229357_at BF060767 ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 (aggrecanase-2) -5.05
213258_at BF511231 TFPI Tissue factor pathway inhibitor -5.025
205798_at NM_002185 IL7R interleukin 7 receptor -5
219935_at NM_007038 ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 (aggrecanase-2) -4.81
212558_at BF508662 SPRY1 sprouty homolog 1, antagonist of FGF signaling -4.63
220936_s_at NM_018267 H2AFJ H2A histone family, member J -4.48
222484_s_at AF144103 CXCL14 chemokine (C-X-C motif) ligand 14 -4.46
228193_s_at AI744499 RGC32 Response gene to complement 32 -4.29
242281_at AW665656 Transcribed locus -4.15
203140_at NM_001706 BCL6 B-cell CLL/lymphoma 6 (zinc finger protein 51) -4
1559739_at AK025141 CHPT1 Choline phosphotransferase 1 -3.97
221234_s_at NM_021813 BACH2 BTB and CNC homology 1, basic leucine zipper transcription factor 2 -3.95
231930_at AL359601 ELMOD1 ELMO domain containing 1 -3.65
205959_at NM_002427 MMP13 matrix metallopeptidase 13 -3.53
231929_at AI458439 MRNA; cDNA DKFZp586O0724 -3.53
206100_at NM_001874 CPM carboxypeptidase M -3.5
235392_at BG403162 IRS1 Insulin receptor substrate 1 -3.34
226231_at AI189509 PAWR PRKC, apoptosis, WT1, regulator -3.32
223449_at AF225425 SEMA6A sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A -3.19
203973_s_at NM_005195 CEBPD CCAAT/enhancer binding protein (C/EBP), delta -3.1
220933_s_at NM_024617 ZCCHC6 zinc finger, CCHC domain containing 6 -3.09  649 
 650 
 651 
 652 
 653 
 654 
655 
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 656 
Figure Legends 657 
 658 
Fig. 1: IGF-I:IGFBP:VN complexes stimulate MCF-7 cell survival. MCF-7 cell viability was 659 
assessed over 24, 48 and 72 hours (A). The data is pooled from three experiments with treatments 660 
tested in at least six wells in each replicate experiment. Asterisks indicate treatments with significant 661 
increases in percent stimulation compared to the VN (control) treatment (p<0.05). Cleaved caspase-7 662 
levels were assessed in MCF-7 cells exposed to FCS, SFM, VN alone or IGF-I+IGFBP-5+VN (B). 663 
Representative blots from multiple independent replicate experiments are shown. Graph (C) denotes 664 
the percentage of cells in different phases of cell cycle for each treatment. Asterisks indicate 665 
treatments with significantly decreased percentage of cells undergoing apoptosis compared to SFM 666 
control (p<0.05). Symbol ‘**’ indicates treatments with significantly increased percentage of cells in 667 
G1 phase compared to SFM control (p<0.05). Data is pooled from three independent replicate 668 
experiments. Drug-induced apoptosis was assessed in MCF-7 cells treated with Adriamycin, 669 
Mitomycin or “no drug” control and were exposed to either IGF-I+IGFBP-3/-5+VN complex, VN 670 
alone, FCS or SFM, and cell viability was assessed after 48 hours using MTS assay (D). Hashes 671 
indicate drug-exposed treatments with significantly increased percent stimulation compared to the 672 
corresponding FCS (control) treatments (p<0.05). Asterisks indicate drug-exposed treatments with 673 
significantly increased percent stimulation compared to the corresponding VN treatments (p<0.05). 674 
Symbol ‘†’ indicates significant decrease in percent cell viability compared to FCS-treated no-drug 675 
control. In all cases, concentrations of the proteins used were: IGF-I (30 ng/mL), IGFBP-3 or -5 (90 676 
ng/mL) and VN (1 μg/mL). Error bars indicate SEM. SFM = serum-free media; FCS = growth media 677 
with 10% fetal calf serum.   678 
 679 
Fig. 2: IGF-1R and the ERK/MAPK and PI3-K/AKT pathways are involved in IGF-680 
I:IGFBP:VN complex-stimulated MCF-7 cell survival. To assess activation of the IGF-1R and 681 
downstream ERK/MAPK and PI3-K/AKT pathways, MCF-7 cells seeded onto wells pre-coated with 682 
VN alone and IGF-I+IGFBP-3+VN (A) or IGF-I+IGFBP-5+VN (B), were lysed and levels of 683 
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corresponding phosphorylated proteins determined by immunoblot analysis. Specific inhibition by the 684 
pharmacological inhibitors was assessed by monitoring levels of phosphorylated ERK 1/2 and AKT in 685 
MCF-7 cells pre-treated with inhibitors for PI3-K/AKT (LY294002) or ERK/MAPK (U0126) or 686 
vehicle control (DMSO) and exposed to VN alone or IGF-I+IGFBP-3/-5+VN complexes (C). 687 
Representative blots from multiple independent replicate experiments are shown. To assess cell 688 
viability (D), MCF-7 cells were pre-treated as described earlier with LY294002, U0126, DMSO (No 689 
treatment; vehicle control) and seeded onto plates pre-coated with IGF-I+IGFBP-3/-5+VN or with 690 
VN alone for 72 hours. Data is expressed as percent stimulation of viability in VN only-vehicle 691 
control treatment.  Data is pooled from three independent replicate experiments with treatments tested 692 
in at least six wells in each replicate experiment. The asterisks indicate treatments with significantly 693 
decreased percent stimulation compared to VN only-vehicle control treatment (p<0.05). Error bars 694 
indicate SEM. BP = IGF binding protein.  695 
 696 
Fig. 3: qRT-PCR validation of differentially expressed genes identified by microarray analysis. 697 
Data from each treatment is expressed as the fold change in gene expression relative to the VN alone 698 
treatment (marked as “-“), with panel A genes being up-regulated in presence of IGF-I+IGFBP-5+VN 699 
and panel B genes being down-regulated in presence of IGF-I+IGFBP-5+VN. The asterisks indicate 700 
treatments with statistically significant fold changes in gene expression compared to VN alone 701 
(control) (p<0.01). Data is represented as mean ± standard error from three independent replicate 702 
experiments. The dashed line indicates a 1.8-fold increase (A) or decrease (B) in gene expression 703 
relative to VN. Graph C compares fold change relative to VN for 11 genes differentially regulated by 704 
the IGF-I+IGFBP-5+VN treatment as determined by microarray analysis (shaded bars) and qRT-PCR 705 
analysis (open bars). Error bars indicate SEM.   706 
 707 
Fig. 4: qRT-PCR analysis of expression of the target gene set in MCF-7 cells and its dependence 708 
on the IGF-1R activation. Data from each treatment is expressed as the fold change in gene 709 
expression relative to the VN alone treatment (marked as “-“). qRT-PCR analysis was performed on 710 
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MCF-7 cells that migrated in response to VN alone, IGF-I+VN, IGFBP-5+VN, IGF-I+IGFBP-5+VN 711 
complex or the [L24][A31]-IGF-I+IGFBP-5+VN complex. The asterisks indicate treatments with 712 
statistically significant differences in gene expression compared to VN alone (control) (p<0.05). Data 713 
is combined from three independent replicate experiments with treatments tested in at least 6 wells in 714 
each replicate experiment. The dashed line indicates a 1.8-fold increase or decrease in gene 715 
expression relative to VN control. Error bars indicate SEM. 716 




